Munich

• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID? Pending
  2025-524443-12-00 4 Post Covid Syndrome (PCS)
• Methylphenidate for Early Awakening in Coma (MEAWAKE) Pending
  2025-524937-19-00 4 Coma due to acute brain injury
• A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in … Pending
  2026-525640-14-00 6 Candidemia
• PREFer Recruiting
  2024-520138-31-00 4 2026-06-01 Early-stage favorable classic Hodgkin lymphoma
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours) Recruiting
  2025-522913-45-00 3 2026-05-21 Advanced relapsed or refractory ovarian cancer
• A Study of JNJ-95597528 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Recruiting
  2025-523464-20-00 4 2026-05-20 Moderate to Severe Atopic Dermatitis
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting
  2024-514754-79-00 4 2026-05-06 Pulmonary Arterial Hypertension (PAH)
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined … Recruiting
  2025-520841-60-00 5 2026-04-24 Delayed consolidation or non-union long bone fracture
• A study to assess the effects of zigakibart on IgA nephropathy. Recruiting
  2024-519699-24-00 4 2026-04-23 IgA nephropathy
• Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On-demand Treatment of Angioedema Attacks in Adults with Acq … Recruiting
  2025-522051-26-00 5 2026-04-23 Acquired Angioedema due to C1 Inhibitor Deficiency
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers Recruiting
  2025-522402-21-00 1 2026-03-27 Advanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A study to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis and coagulopathy Recruiting
  2024-515635-30-00 3 2026-03-24 Coagulopathy
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• KHENERFIN Recruiting
  2025-522361-30-00 5 2026-03-17 Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G variant and A
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia

Showing 73–96 of 1,080 trials